Cargando…

Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review

The use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) in rheumatic diseases is constantly increasing during the last decade. Tofacitinib is a new oral Janus Kinase (JAK) inhibitor, approved for rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colit...

Descripción completa

Detalles Bibliográficos
Autores principales: Grigoropoulos, Ioannis, Thomas, Konstantinos, Christoforou, Panagiotis, Fanidi, Iliana, Papavdi, Maria, Kyriakou, Fani, Deutsch, Melanie, Pirounaki, Maria, Vassilopoulos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Mediterranean Journal of Rheumatology (MJR) 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045858/
https://www.ncbi.nlm.nih.gov/pubmed/32185360
http://dx.doi.org/10.31138/mjr.30.3.167
_version_ 1783501859574513664
author Grigoropoulos, Ioannis
Thomas, Konstantinos
Christoforou, Panagiotis
Fanidi, Iliana
Papavdi, Maria
Kyriakou, Fani
Deutsch, Melanie
Pirounaki, Maria
Vassilopoulos, Dimitrios
author_facet Grigoropoulos, Ioannis
Thomas, Konstantinos
Christoforou, Panagiotis
Fanidi, Iliana
Papavdi, Maria
Kyriakou, Fani
Deutsch, Melanie
Pirounaki, Maria
Vassilopoulos, Dimitrios
author_sort Grigoropoulos, Ioannis
collection PubMed
description The use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) in rheumatic diseases is constantly increasing during the last decade. Tofacitinib is a new oral Janus Kinase (JAK) inhibitor, approved for rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colitis. Safety data of tofacitinib derived from randomized controlled trials and long-term extension studies has demonstrated a moderate increase in the risk for common serious infections. We describe a case of Pneumocystis jirovecii pneumonia (PJP) in a woman on tofacitinib therapy for RA. Although tofacitinib use has been associated with the development of opportunistic infections, PJP has been rarely reported. PJP should be included in the differential diagnosis of patients with autoimmune disorders under newer oral JAK inhibitors therapy who present with fever, hypoxia and pulmonary infiltrates.
format Online
Article
Text
id pubmed-7045858
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Mediterranean Journal of Rheumatology (MJR)
record_format MEDLINE/PubMed
spelling pubmed-70458582020-03-17 Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review Grigoropoulos, Ioannis Thomas, Konstantinos Christoforou, Panagiotis Fanidi, Iliana Papavdi, Maria Kyriakou, Fani Deutsch, Melanie Pirounaki, Maria Vassilopoulos, Dimitrios Mediterr J Rheumatol Review The use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) in rheumatic diseases is constantly increasing during the last decade. Tofacitinib is a new oral Janus Kinase (JAK) inhibitor, approved for rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colitis. Safety data of tofacitinib derived from randomized controlled trials and long-term extension studies has demonstrated a moderate increase in the risk for common serious infections. We describe a case of Pneumocystis jirovecii pneumonia (PJP) in a woman on tofacitinib therapy for RA. Although tofacitinib use has been associated with the development of opportunistic infections, PJP has been rarely reported. PJP should be included in the differential diagnosis of patients with autoimmune disorders under newer oral JAK inhibitors therapy who present with fever, hypoxia and pulmonary infiltrates. The Mediterranean Journal of Rheumatology (MJR) 2019-09-30 /pmc/articles/PMC7045858/ /pubmed/32185360 http://dx.doi.org/10.31138/mjr.30.3.167 Text en © 2019 The Mediterranean Journal of Rheumatology (MJR) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Review
Grigoropoulos, Ioannis
Thomas, Konstantinos
Christoforou, Panagiotis
Fanidi, Iliana
Papavdi, Maria
Kyriakou, Fani
Deutsch, Melanie
Pirounaki, Maria
Vassilopoulos, Dimitrios
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
title Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
title_full Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
title_fullStr Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
title_full_unstemmed Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
title_short Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
title_sort pneumocystis jirovecii pneumonia after initiation of tofacitinib therapy in rheumatoid arthritis: case-based review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045858/
https://www.ncbi.nlm.nih.gov/pubmed/32185360
http://dx.doi.org/10.31138/mjr.30.3.167
work_keys_str_mv AT grigoropoulosioannis pneumocystisjiroveciipneumoniaafterinitiationoftofacitinibtherapyinrheumatoidarthritiscasebasedreview
AT thomaskonstantinos pneumocystisjiroveciipneumoniaafterinitiationoftofacitinibtherapyinrheumatoidarthritiscasebasedreview
AT christoforoupanagiotis pneumocystisjiroveciipneumoniaafterinitiationoftofacitinibtherapyinrheumatoidarthritiscasebasedreview
AT fanidiiliana pneumocystisjiroveciipneumoniaafterinitiationoftofacitinibtherapyinrheumatoidarthritiscasebasedreview
AT papavdimaria pneumocystisjiroveciipneumoniaafterinitiationoftofacitinibtherapyinrheumatoidarthritiscasebasedreview
AT kyriakoufani pneumocystisjiroveciipneumoniaafterinitiationoftofacitinibtherapyinrheumatoidarthritiscasebasedreview
AT deutschmelanie pneumocystisjiroveciipneumoniaafterinitiationoftofacitinibtherapyinrheumatoidarthritiscasebasedreview
AT pirounakimaria pneumocystisjiroveciipneumoniaafterinitiationoftofacitinibtherapyinrheumatoidarthritiscasebasedreview
AT vassilopoulosdimitrios pneumocystisjiroveciipneumoniaafterinitiationoftofacitinibtherapyinrheumatoidarthritiscasebasedreview